Crosstalk between ROR1 and the pre-B-Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia

par Bicocca, Vincent T., Chang, Bill H., Masouleh, Behzad Kharabi, Muschen, Markus, Loriaux, Marc M., Druker, Brian J., Tyner, Jeffrey W.
Publié 2012

HitWalker: variant prioritization for personalized functional cancer genomics

par Bottomly, Daniel, Wilmot, Beth, Tyner, Jeffrey W., Eide, Christopher A., Loriaux, Marc M., Druker, Brian J., McWeeney, Shannon K.
Publié 2013

Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine

par Bottomly, Daniel, Ryabinin, Peter A, Tyner, Jeffrey W, Chang, Bill H, Loriaux, Marc M, Druker, Brian J, McWeeney, Shannon K, Wilmot, Beth
Publié 2013

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma

par Siegel, Matthew B., Liu, Selina Qiuying, Davare, Monika A., Spurgeon, Stephen E., Loriaux, Marc M., Druker, Brian J., Scott, Emma C., Tyner, Jeffrey W.
Publié dans Oncotarget (2015)

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

par Tyner, Jeffrey W., Bumm, Thomas G., Deininger, Jutta, Wood, Lisa, Aichberger, Karl J., Loriaux, Marc M., Druker, Brian J., Burns, Christopher J., Fantino, Emmanuelle, Deininger, Michael W.
Publié 2010

SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia

par Paiva, Cody, Rowland, Taylor A., Sreekantham, Bhargava, Godbersen, Claire, Best, Scott R., Kaur, Prabhjot, Loriaux, Marc M., Spurgeon, Stephen E.F., Danilova, Olga V., Danilov, Alexey V.
Publié dans Haematologica (2017)

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor

par Burke, Russell T, Meadows, Sarah, Loriaux, Marc M, Currie, Kevin S., Mitchell, Scott A., Maciejewski, Patricia, Clarke, Astrid S., Dipaolo, Julie A., Druker, Brian J., Lannutti, Brian J., Spurgeon, Stephen E.
Publié 2014

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition

par Fleischman, Angela G., Maxson, Julia E., Luty, Samuel B., Agarwal, Anupriya, Royer, Lacey R., Abel, Melissa L., MacManiman, Jason D., Loriaux, Marc M., Druker, Brian J., Tyner, Jeffrey W.
Publié 2013

RNAi screen for rapid therapeutic target identification in leukemia patients

par Tyner, Jeffrey W., Deininger, Michael W., Loriaux, Marc M., Chang, Bill H., Gotlib, Jason R., Willis, Stephanie G., Erickson, Heidi, Kovacsovics, Tibor, O'Hare, Thomas, Heinrich, Michael C., Druker, Brian J.
Publié 2009

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients

par Tyner, Jeffrey W., Erickson, Heidi, Deininger, Michael W. N., Willis, Stephanie G., Eide, Christopher A., Levine, Ross L., Heinrich, Michael C., Gattermann, Norbert, Gilliland, D. Gary, Druker, Brian J., Loriaux, Marc M.
Publié 2009

Met receptor sequence variants R970C and T992I lack transforming capacity

par Tyner, Jeffrey W., Fletcher, Luke B., Wang, Ellen Q., Yang, Wayne F., Rutenberg-Schoenberg, Michael L., Beadling, Carol, Mori, Motomi, Heinrich, Michael C., Deininger, Michael W., Druker, Brian J., Loriaux, Marc M.
Publié 2010

Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

par Gozgit, Joseph M., Wong, Matthew J., Wardwell, Scott, Tyner, Jeffrey W., Loriaux, Marc M., Mohemmad, Qurish K., Narasimhan, Narayana I., Shakespeare, William C., Wang, Frank, Druker, Brian J., Clackson, Tim, Rivera, Victor M.
Publié 2011

The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia

par Spurgeon, Stephen E., Coffey, Greg, Fletcher, Luke B., Burke, Russell, Tyner, Jeffrey W., Druker, Brian J., Betz, Andreas, DeGuzman, Francis, Pak, Yvonne, Baker, Dale, Pandey, Anjali, Hollenbach, Stanley J., Sinha, Uma, Loriaux, Marc M.
Publié 2013

Therapeutically targetable ALK mutations in leukemia

par Maxson, Julia E., Davare, Monika A., Luty, Samuel B., Eide, Christopher A., Chang, Bill H., Loriaux, Marc M., Tognon, Cristina E., Bottomly, Daniel, Wilmot, Beth, McWeeney, Shannon K., Druker, Brian J., Tyner, Jeffrey W.
Publié dans Cancer Res (2015)

The Colony Stimulating Factor 3 Receptor T640N mutation is oncogenic, sensitive to JAK inhibition, and mimics T618I

par Maxson, Julia E., Luty, Samuel B., MacManiman, Jason D., Paik, Jason C., Gotlib, Jason, Greenberg, Peter, Bahamadi, Swaleh, Savage, Samantha L., Abel, Melissa L., Eide, Christopher A., Loriaux, Marc M., Stevens, Emily A., Tyner, Jeffrey W.
Publié dans Clin Cancer Res (2015)

An Adaptive Src-PDGFRA-Raf Axis in Rhabdomyosarcoma

par Abraham, Jinu, Chua, Ying Xuan, Glover, Jason M., Tyner, Jeffrey W., Loriaux, Marc M., Kilcoyne, Aoife, Giles, Francis J., Nelon, Laura D., Carew, Jennifer S., Ouyang, Yongjian, Michalek, Joel E., Pal, Ranadip, Druker, Brian J., Rubin, Brian P., Keller, Charles
Publié 2012

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

par Lannutti, Brian J., Meadows, Sarah A., Herman, Sarah E. M., Kashishian, Adam, Steiner, Bart, Johnson, Amy J., Byrd, John C., Tyner, Jeffrey W., Loriaux, Marc M., Deininger, Mike, Druker, Brian J., Puri, Kamal D., Ulrich, Roger G., Giese, Neill A.
Publié 2011

Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression

par Beer, Philip A., Knapp, David J. H. F., Miller, Paul H., Kannan, Nagarajan, Sloma, Ivan, Heel, Kathy, Babovic, Sonja, Bulaeva, Elizabeth, Rabu, Gabrielle, Terry, Jefferson, Druker, Brian J., Loriaux, Marc M., Loeb, Keith R., Radich, Jerald P., Erber, Wendy N., Eaves, Connie J.
Publié dans Blood (2015)

Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples

par Edwards V, David K., Sweeney, David Tyler, Ho, Hibery, Eide, Christopher A., Rofelty, Angela, Agarwal, Anupriya, Liu, Selina Qiuying, Danilov, Alexey V., Lee, Patrice, Chantry, David, McWeeney, Shannon K., Druker, Brian J., Tyner, Jeffrey W., Spurgeon, Stephen E., Loriaux, Marc M.
Publié dans Oncotarget (2018)

TSLP Signaling Network Revealed by SILAC-Based Phosphoproteomics

par Zhong, Jun, Kim, Min-Sik, Chaerkady, Raghothama, Wu, Xinyan, Huang, Tai-Chung, Getnet, Derese, Mitchell, Christopher J., Palapetta, Shyam M., Sharma, Jyoti, O'Meally, Robert N., Cole, Robert N., Yoda, Akinori, Moritz, Albrecht, Loriaux, Marc M., Rush, John, Weinstock, David M., Tyner, Jeffrey W., Pandey, Akhilesh
Publié 2012